Abstract
e18076 Background: Ruxolitinib is the only approved therapy for pts with myelofibrosis and polycythemia vera. However, its use in pts not participating in clinical studies has been poorly described. Methods: We reviewed medical records of 45 pts with MPNs (35 post-ET or -PV MF/PMF; 10 CMML/ET/PV/MDS-MPN) that have been treated at our center with ruxolitinib off clinical study. Results: Median duration of therapy was 12.2 months (0.9-28.5) and median follow-up 17.1 months (5.4-36.5). 73% had JAK2V617F mutation; 25 pts had diploid karyotype. Median spleen size by palpation was 11.5 cm (0-28). Fatigue was the most common symptom. 11% started therapy at 20mg twice daily, others started at reduced doses mainly due to anemia or thrombocytopenia. Eighteen of 35 pts with palpable splenomegaly (53%) had a reduction in spleen size by ≥ 50% (complete resolution in 11pts (32%)). Median time to best spleen response was 3 months (0.4-23.6). Improvement in quality of life, including fatigue, weight gain, resolution of f...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
